※ 출처: ClinicalTrials.gov
총 336건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, NCT No, 개시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 NCT No 개시일자
1 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Diffuse Large B-Cell Lymphoma Drug: Epcoritamab|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone AbbVie|Genmab Phase 3 2023-02-08
2 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥0% (MK-3475-D46) Carcinoma, Non-Small-Cell Lung Biological: Sacituzumab Govitecan|Biological: Pembrolizumab Merck Sharp & Dohme LLC|Gilead Sciences Phase 3 2023-02-06
3 Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered Erectile Dysfunction Following Radical Prostatectomy|Erectile Dysfunction|Prostate Cancer|Radical Prostatectomy Drug: BZ371A Biozeus Biopharmaceutical S.A.|Azidus Brasil Scientific Research and Development Ltda Phase 1 2022-11-16
4 A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer Carcinoma, Non-small-Cell Lung Drug: Amivantamab|Drug: Lazertinib|Drug: Carboplatin|Drug: Pemetrexed|Drug: Direct Oral Anticoagulant (DOAC)|Drug: Low Molecular Weight Heparin (LMWH) Janssen Research & Development, LLC Phase 2 2022-11-11
5 Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis Eosinophilic Esophagitis Biological: Tezepelumab|Other: Placebo AstraZeneca|Amgen Phase 3 2022-11-10
6 Clinical Study of DTX301 AAV- Mediated Gene Transfer for Ornithine Transcarbamylase(OTC) Deficiency OTC Deficiency Genetic: DTX301|Other: Placebo|Drug: Oral Corticosteroids|Drug: Placebo for oral corticosteroids|Drug: Sodium Acetate Ultragenyx Pharmaceutical Inc Phase 3 2022-10-18
7 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) Hodgkin Lymphoma Biological: favezelimab/pembrolizumab|Drug: bendamustine|Drug: gemcitabine Merck Sharp & Dohme LLC Phase 3 2022-10-18
8 A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Relapsed or Refractory Multiple Myeloma Drug: Talquetamab|Drug: Daratumumab|Drug: Pomalidomide|Drug: Dexamethasone Janssen Research & Development, LLC Phase 3 2022-10-13
9 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma Follicular Lymphoma (FL) Drug: Epcoritamab|Drug: Rituximab|Drug: Lenalidomide AbbVie|Genmab Phase 3 2022-09-20
10 A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow SGA, Turner Syndrome, Noonan Syndrome, ISS Drug: Somapacitan|Drug: Norditropin® Novo Nordisk A/S Phase 3 2022-08-10